[go: up one dir, main page]

PL2024367T3 - Tetrahydropirolopirymidynodiony i ich zastosowanie jako inhibitory ludzkiej elastazy neutrofilowej - Google Patents

Tetrahydropirolopirymidynodiony i ich zastosowanie jako inhibitory ludzkiej elastazy neutrofilowej

Info

Publication number
PL2024367T3
PL2024367T3 PL07732669T PL07732669T PL2024367T3 PL 2024367 T3 PL2024367 T3 PL 2024367T3 PL 07732669 T PL07732669 T PL 07732669T PL 07732669 T PL07732669 T PL 07732669T PL 2024367 T3 PL2024367 T3 PL 2024367T3
Authority
PL
Poland
Prior art keywords
neutrophil elastase
tetrahydropyrrolopyrimidinediones
human neutrophil
elastase inhibitors
inhibitors
Prior art date
Application number
PL07732669T
Other languages
English (en)
Inventor
Nicholas Charles Ray
Harry Finch
Christine Edwards
Elizabeth O'connor
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608844A external-priority patent/GB0608844D0/en
Priority claimed from GB0612544A external-priority patent/GB0612544D0/en
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL2024367T3 publication Critical patent/PL2024367T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL07732669T 2006-05-04 2007-05-03 Tetrahydropirolopirymidynodiony i ich zastosowanie jako inhibitory ludzkiej elastazy neutrofilowej PL2024367T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0608844A GB0608844D0 (en) 2006-05-04 2006-05-04 Enzyme inhibitors
GB0612544A GB0612544D0 (en) 2006-06-23 2006-06-23 Enzyme inhibitors
PCT/GB2007/001638 WO2007129060A1 (en) 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
EP07732669A EP2024367B1 (en) 2006-05-04 2007-05-03 Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors

Publications (1)

Publication Number Publication Date
PL2024367T3 true PL2024367T3 (pl) 2011-05-31

Family

ID=38226415

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07732669T PL2024367T3 (pl) 2006-05-04 2007-05-03 Tetrahydropirolopirymidynodiony i ich zastosowanie jako inhibitory ludzkiej elastazy neutrofilowej

Country Status (20)

Country Link
US (1) US8957082B2 (pl)
EP (1) EP2024367B1 (pl)
JP (1) JP4999920B2 (pl)
AT (1) ATE480543T1 (pl)
AU (1) AU2007246889B2 (pl)
BR (1) BRPI0711169A2 (pl)
CA (1) CA2657956C (pl)
CY (1) CY1111437T1 (pl)
DE (1) DE602007009095D1 (pl)
DK (1) DK2024367T3 (pl)
EA (1) EA018061B1 (pl)
IL (1) IL194843A (pl)
MX (1) MX2008013996A (pl)
NO (1) NO20084502L (pl)
NZ (1) NZ572250A (pl)
PL (1) PL2024367T3 (pl)
PT (1) PT2024367E (pl)
SI (1) SI2024367T1 (pl)
WO (1) WO2007129060A1 (pl)
ZA (1) ZA200809250B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
ATE480543T1 (de) 2006-05-04 2010-09-15 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase
US8198288B2 (en) 2006-05-04 2012-06-12 Pulmagen Therapeutics (Inflammation) Limited Tetrahydropyrrolopyrimidinediones and their use in therapy
WO2009013444A1 (en) * 2007-07-25 2009-01-29 Argenta Discovery Limited Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
US20110003858A1 (en) * 2006-09-04 2011-01-06 Bergstroem Lena Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
EA017297B1 (ru) 2007-11-06 2012-11-30 Астразенека Аб Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
GB0721866D0 (en) * 2007-11-07 2007-12-19 Argenta Discovery Ltd Pharmaceutical compounds having dual activities
WO2009060206A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 3,4,6,7-tetrahydro-1h-pyrrolo[3,4-d]pyrimidine-2,5-diones and their therapeutic use
WO2009060158A1 (en) * 2007-11-07 2009-05-14 Argenta Discovery Limited 4- (4-cyanophenyl) -1- (3-trifluoromethylphenyl) -3,4, 6, 7-tetrahydro-1h-pyrrolo [3, 4- d] pyrimidine-2, 5-dione derivatives and their use as human neutrophil elastase inhibitors
DE102008022521A1 (de) * 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
DE102008052013A1 (de) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
EP2234985B1 (de) 2007-12-20 2012-03-07 Bayer Pharma Aktiengesellschaft 4- (4-cyano-2-thioaryl) -dihydropyrimidinone und ihre verwendung
DE102007061766A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag 4-(4-Cyano-2-thioaryl)-dihydropyrimidinone und ihre Verwendung
GB0817429D0 (en) * 2008-09-23 2008-10-29 Argenta Discovery Ltd Enzyme inhibitors
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
MA33070B1 (fr) 2009-01-30 2012-02-01 Chiesi Farma Spa Pyrrolopyrimidinedione dimere et son utilisation dans le traitement de maladies respiratoires
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
KR20120099639A (ko) 2009-10-02 2012-09-11 아스트라제네카 아베 호중구 엘라스타제의 억제제로서 사용되는 2-피리돈 화합물
GB201004178D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
GB201004179D0 (en) * 2010-03-12 2010-04-28 Pulmagen Therapeutics Inflamma Enzyme inhibitors
DE102010030187A1 (de) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft 4-Cyan-2-sulfonylphenyl)pyrazolyl-substituierte Pyridinone und Pyrazinone und ihre Verwendung
BR112014005669A2 (pt) * 2011-09-14 2017-04-04 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
WO2015091281A1 (en) 2013-12-16 2015-06-25 Chiesi Farmaceutici S.P.A. Tetrahydrotriazolopyrimidine derivatives as human neutrophil elastase inhibitors
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9487528B2 (en) 2014-06-09 2016-11-08 Chiesi Farmaceutici S.P.A. Compounds
US9290457B2 (en) 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) * 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) * 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
AU2016232270B2 (en) 2015-03-18 2020-09-03 Ph Pharma Co., Ltd. Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
LT4106757T (lt) 2020-04-16 2023-11-10 Mereo Biopharma 4 Limited Neutrofilų elastazės inhibitoriaus alvelestato panaudojimas kvėpavimo sistemos ligų, nulemtų alfa-1 antitripsino nepakankamumo, gydymui
AU2022373971A1 (en) 2021-10-20 2024-04-04 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9626643D0 (en) 1996-12-21 1997-02-12 Astra Pharma Prod Compounds
PE107899A1 (es) 1997-09-09 1999-11-17 Glaxo Group Ltd Derivados de pirrolopirrolona como inhibidores de elastasa leucocitaria
US6630476B2 (en) 2000-07-07 2003-10-07 Bristol-Myers Squibb Pharma Company Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
KR20050042190A (ko) 2002-09-10 2005-05-04 바이엘 헬스케어 아게 급성 및 만성 염증성, 허혈성 및 재형성 과정에 대한 치료제로서의 피리미디논 유도체
EP1539710B1 (en) * 2002-09-10 2010-10-27 Bayer Schering Pharma Aktiengesellschaft Heterocyclic derivatives
GB0502258D0 (en) * 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
GB0520743D0 (en) * 2005-10-12 2005-11-23 Argenta Discovery Ltd Compounds and their use
ATE480543T1 (de) 2006-05-04 2010-09-15 Pulmagen Therapeutics Inflamma Tetrahydropyrrolopyrimidindione und ihre verwendung als inhibitoren der humanen neutrophilen elastase

Also Published As

Publication number Publication date
HK1130794A1 (en) 2010-01-08
BRPI0711169A2 (pt) 2011-08-23
EP2024367A1 (en) 2009-02-18
SI2024367T1 (sl) 2011-04-29
CA2657956C (en) 2015-01-06
EA018061B1 (ru) 2013-05-30
MX2008013996A (es) 2009-01-14
ZA200809250B (en) 2010-02-24
WO2007129060A1 (en) 2007-11-15
US8957082B2 (en) 2015-02-17
AU2007246889B2 (en) 2011-03-10
NO20084502L (no) 2008-11-26
DE602007009095D1 (de) 2010-10-21
ATE480543T1 (de) 2010-09-15
CY1111437T1 (el) 2015-08-05
NZ572250A (en) 2011-10-28
PT2024367E (pt) 2010-12-03
DK2024367T3 (da) 2011-01-03
US20120202826A1 (en) 2012-08-09
EP2024367B1 (en) 2010-09-08
EA200870391A1 (ru) 2009-06-30
AU2007246889A1 (en) 2007-11-15
JP4999920B2 (ja) 2012-08-15
JP2009535389A (ja) 2009-10-01
IL194843A0 (en) 2009-08-03
CA2657956A1 (en) 2007-11-15
IL194843A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
ZA200809250B (en) Tetrahydropyrrolopyrimidinediones and their use as human neutrophil elastase inhibitors
EP1851237A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TREATING OR PREVENTING BONE DISORDERS
MX2010014233A (es) Compuestos quimicos 251.
TNSN07111A1 (en) Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
ZA200703601B (en) Medicaments for the treatment or prevention of fibriotic diseases
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
MY148851A (en) Dihydropyridine derivatives as useful as protein kinase inhibitors
TW200605886A (en) Indazoles useful in treating cardiovascular diseases
DE602007005120D1 (de) 2-pyridonderivate zur behandlung von krankheiten oder leiden, bei denen eine inhibierung der aktivität der neutrophilen elastase von nutzen ist
ZA200801511B (en) Novel diazaspiroalkanes and their use for treatment of CCR8 medicated diseases
UA107783C2 (en) Isoindoline compounds for use in treating cancer
IN2012DN00971A (pl)
UA96785C2 (uk) Заміщені похідні оксиндолу та їх застосування як лігандів рецептора вазопресину
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
IL193252A0 (en) N-hydroxyacrylamide compounds
MX2009002960A (es) Inhibidores de serina hidrolasa.
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
ATE529430T1 (de) Caspase-hemmer-propharmaka
WO2009130615A3 (de) Verwendung von deuteriumoxid als elastase-inhibitor
NO20080781L (no) GLEPP-inhibitorer i behandlingen av autoimmune og/eller inflammatoriske sykdommer
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral